Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: 350 mg leronlimab|DRUG: 525 mg leronlimab|DRUG: 700 mg leronlimab|DRUG: AUC 5 Carboplatin|DRUG: Maximum Tolerated Dose (MTD) of leronlimab
Sponsor: CytoDyn, Inc.
Collaborators: Amarex Clinical Research